CDC73 and Hyperparathyroidism-jaw tumor syndrome: This may contribute to tumor suppressor activity attributed to CDC73, which is mutated in hyperparathyroidism-jaw tumor syndrome (HPT-JT), exhibiting a loss of function mutation in more than 80% of these malignancies [31, 32].